** charts after earnings **
SciClone Pharma beats by $0.14, beats on revs; guidesFY15 EPS above estimate, reaffirms FY15 revs guidance:
- Reports Q3 (Sep) earnings of $0.26 per share, excluding non-recurring items,$0.14 better than the single analyst estimate of $0.12; revenues rose 25.1% year/year to $42.9 mln vs the $40.61 mln single analyst estimate.
- Co issues guidance for FY15, sees EPS of $0.93-0.97, excluding non-recurring items, vs. $0.33 single analyst estimate; sees FY15 revs of $153-158 mln vs. $154.44 mln single analyst estimate.
No comments:
Post a Comment